Drug Profile
Research programme: drug discovery - Janssen/Johnson &Johnson Innovation/Toronto Innovation Acceleration Partners
Latest Information Update: 07 Oct 2020
Price :
$50
*
At a glance
- Originator Janssen Inc; Johnson & Johnson; MaRS Innovation
- Developer Janssen Inc; Johnson & Johnson; Toronto Innovation Acceleration Partners
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Undefined in Canada
- 25 Nov 2013 Early research in Undefined indication in Canada (unspecified route)